June 15 (Reuters) - iCo Therapeutics Inc ICO.V
* Says it will hold a pre IND meeting with division of transplantation and ophthalmology, US FDA on June 21, 2017
* Says discussions will focus on a proprietary dual action Glaucoma Asset with a Novel mechanism of action that reduces intraocular pressure Source text for Eikon: Further company coverage: ICO.V